For investors
The data layer for medication at home.
Nexus is a connected medication ecosystem for private patients on injectable and complex treatments. The Nexus app turns the pharmacy label and the clinician’s instructions into one plan, and the Nexus device keeps each medicine in its required conditions and records each dose as it is removed, building a record of real-world medicine use that is rarely captured today.
The record comes from Nexus, not from memory.
Most products in this space either keep medicine cold or rely on patients to report what they took. Nexus holds the storage conditions and records each dose in the same Med Pod, so storage and dosing sit side by side in one record that travels with the patient.
The scale of the problem
11.6%
of biologic injectors stayed within the recommended 2 to 8°C range throughout transport and home storage.¹
Source 1
26 to 49%
of patients on subcutaneous biologics have unused injectors at home.¹
Source 1
1 in 2
Adherence to long-term therapies in developed countries averages 50%.²
Source 2
1. de Jong MJ, Pierik MJ, Peters A, et al. Exploring conditions for redistribution of anti-tumor necrosis factors to reduce spillage: a study on the quality of anti-tumor necrosis factor home storage. J Gastroenterol Hepatol. 2018;33(2):426-430.
2. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003.
Our own market sizing is set out in the investor deck.
Progress to date
Nexus launches in 2027, with the app and device together.
Product
Three Med Pods in development, with working prototypes and thermal testing under way.
Regulatory
Classified as a Class I medical device under UK MDR 2002, on the self-declaration route.
Intellectual property
Patent applications filed in the UK, the US and under the PCT, covering the device and the record it produces.
Details shared at due diligence
Manufacturing
An engineering partner is engaged and building the prototypes.
Engaged, 2026
Our founder
Francesca (Chess) Howard
Chess Howard founded Vita Panacea after fourteen years in the Lloyd's of London market, where she structured risk transfer for Healthcare and Life Sciences clients. Her career began on Wall Street at eighteen, and she went on to specialise in large, multi-jurisdictional risk, from hospital groups and life sciences companies to clinical trial programmes spanning several regulatory regimes. By thirty she was heading a Healthcare and Life Sciences division.
She now serves as a Non-Executive Director of a specialist Lloyd’s capacity vehicle, and sits on the advisory board of a leading UK wholesale broking body. She is the sole inventor of Nexus.
Leadership
Francesca Howard
Founder & CEO
Sean Mooney
CFO
Jodie Bridge
Marketing and Partnerships Lead
Trisha Durant
Strategic Adviser, Commercial
Dr Cem Baydar
Strategic Adviser, Investment
Where the company stands
Each item shows exactly where it stands, so filed means not yet granted, and classified means not yet registered with the MHRA.
Red Dot
- Detail
Design Concept award for the Nexus device, 2026
- Status
Awarded
- Date
2026
Regulatory
- Detail
Classified Class I under UK MDR 2002. MHRA submission and UKCA marking in progress.
- Status
Classified
- Date
2026
Intellectual property
- Detail
Patent applications and trade marks filed.
- Status
Filed
- Date
2026
Software
- Detail
Fully coded app, with a medicines repository and label scanning (OCR).
- Status
Built
- Date
2026
Letters of intent
- Detail
Signed with private clinical providers
- Status
Signed
- Date
2026
Pilot programme
- Detail
A fully funded pilot programme, running from June to August 2027. Expressions of interest close on 1 January 2027.
- Status
Planned
- Date
June 2027
Talk to us about investing in Nexus
Request our investor deck, a call or both, and we will respond personally.